Predicting responses to chemotherapy in breast cancer: from bench to bedside

被引：0
|
作者：
Akashi-Tanaka, Sadako [1 ]
机构：
[1] Natl Canc Ctr, Div Breast Surg, Chuo Ku, Tokyo 1040045, Japan
来源：
BREAST CANCER | 2010年 / 17卷 / 02期
关键词：
Breast cancer; Predictive factor; Gene expression profile; Chemotherapy; Pharmacogenomics; GENE-EXPRESSION; NEOADJUVANT CHEMOTHERAPY; DOCETAXEL; EFFICACY; THERAPY; TRASTUZUMAB; SUBTYPES; MARKER; WOMEN; TRIAL;
D O I：
10.1007/s12282-009-0166-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recent progress in biotechnology, notably microarray analyses, makes it possible to examine the genome-based characteristics of tumors with different prognoses and predict responses to chemotherapy. Furthermore, pharmacogenomic techniques are expected to predict the optimal regimen for individual patients that will provide high benefits with reduced toxicity. Some predictive or prognostic tests for breast cancer are now moving from bench to bedside.
引用
收藏
页码：92 / 96
页数：5
相关论文
共 50 条
  • [21] Genetic susceptibility in cervical cancer: From bench to bedside
    Bahrami, Afsane
    Hasanzadeh, Malihe
    Shahidsales, Soodabeh
    Farazestanian, Marjaneh
    Hassanian, Seyed Mahdi
    Ahmadi, Mehrdad Moetamani
    Maftouh, Mina
    Gharib, Masoumeh
    Yousefi, Zohreh
    Kadkhodayan, Sima
    Ferns, Gordon A.
    Avan, Amir
    JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (03) : 1929 - 1939
  • [22] Neoadjuvant Chemotherapy in the Treatment of Breast Cancer
    Redden, Meredith H.
    Fuhrman, George M.
    SURGICAL CLINICS OF NORTH AMERICA, 2013, 93 (02) : 493 - +
  • [23] Predicting response to immunotherapy in non-small cell lung cancer- from bench to bedside
    Montoya, Chris
    Spieler, Benjamin
    Welford, Scott M.
    Kwon, Deukwoo
    Pra, Alan Dal
    Lopes, Gilberto
    Mihaylov, Ivaylo B.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [24] Adjuvant and neoadjuvant chemotherapy of breast cancer
    Untch, M.
    Thomssen, C.
    ONKOLOGE, 2015, 21 (03): : 231 - 238
  • [25] Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis
    Nishimura, Reiki
    Osako, Tomofumi
    Okumura, Yasuhiro
    Hayashi, Mitsuhiro
    Arima, Nobuyuki
    BREAST CANCER, 2010, 17 (04) : 269 - 275
  • [26] Adjuvant and neoadjuvant chemotherapy of breast cancer
    Untch, M.
    Thomssen, C.
    ONKOLOGE, 2015, 21 (03): : 231 - 238
  • [27] Update on current and new potential immunotherapies in breast cancer, from bench to bedside
    Alaluf, Emmanuelle
    Shalamov, Michal Mia
    Sonnenblick, Amir
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [28] Identifying the role of PTPN12 expression in predicting the efficacy of capecitabine to neoadjuvant chemotherapy in breast cancer treatment
    Wang, Y. -Y.
    Liu, H.
    Mao, X. -Y.
    Jin, F.
    Ma, B.
    Jiang, J. -Y.
    Cao, Y.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2016, 20 (16) : 3400 - 3409
  • [29] The neoadjuvant approach in breast cancer treatment: it is not just about chemotherapy anymore
    Caudle, Abigail S.
    Hunt, Kelly K.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2011, 23 (01) : 31 - 36
  • [30] Neoadjuvant Chemotherapy for Breast Cancer with Weekly Nab-paclitaxel Followed by Epirubicin and Cyclophosphamide - Results of a Case Series
    Hahn, Antje
    Schlotter, Claus M.
    Rossmanith, Winfried G.
    Ulmer, Hans-Ulrich
    Staiger, Hans-Juergen
    Villena, Carlos
    IN VIVO, 2014, 28 (02): : 235 - 241
12345